Literature DB >> 15028149

Neutralizing antibody against interleukin-6 attenuates posthemorrhagic vasospasm in the rat femoral artery model.

George Bowman1, Sanat Dixit, Robert H Bonneau, Vernon M Chinchilli, Kevin M Cockroft.   

Abstract

OBJECTIVE: The degree to which inflammation contributes to the development of posthemorrhagic vasospasm is controversial. In the present study, we investigated the relationship between various inflammatory cytokines (tumor necrosis factor-alpha, interleukin [IL]-1alpha, IL-1beta, and IL-6) and the development of experimental vasospasm.
METHODS: Posthemorrhagic vasospasm was produced in the rat femoral artery model. A latex pouch was placed around each femoral artery, and one pouch was injected with autologous blood and the other with saline as an internal control. Animals were killed at various time points (1 h to 16 d) after surgery (blood exposure), and the degree of vasospasm was assessed by image analysis of artery cross sectional area. Levels of inflammatory cytokines were determined by enzyme-linked immunosorbent assay, and the ability of a polyclonal antibody against rat IL-6 to inhibit vasospasm was tested.
RESULTS: The rat femoral artery model produced a biphasic vasospasm response, with maximal chronic delayed vasospasm occurring at 8 days after hemorrhage. Enzyme-linked immunosorbent assay revealed a significant increase in IL-6 concentrations in blood-exposed arteries relative to saline-exposed arteries at multiple time points (6, 12, 24, and 48 h) after hemorrhage (P < 0.0001). A relative increase in IL-1alpha levels was noted at 24 hours (P < 0.01). IL-1beta levels were similarly elevated in both blood- and saline-exposed arteries, and tumor necrosis factor-alpha levels were not detectable. Administration of a neutralizing polyclonal antibody against rat IL-6 directly into the blood-exposed periarterial pouch at the time of initial surgery resulted in a dose-dependent reduction in the degree of vasospasm compared with vehicle-treated controls at 8 days after hemorrhage (P < 0.05).
CONCLUSIONS: These results indicate that cytokine-mediated inflammation is active in the setting of posthemorrhagic vasospasm produced by the rat femoral artery model. In particular, the profound increase in IL-6 levels after exposure to hemorrhage and the ability of a polyclonal antibody against IL-6 to reduce vasospasm suggest that IL-6 may play a prominent role in the development of vasospasm in this model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028149     DOI: 10.1227/01.neu.0000108981.73153.6e

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  16 in total

Review 1.  Mechanisms of neuroinflammation and inflammatory mediators involved in brain injury following subarachnoid hemorrhage.

Authors:  Takeshi Okada; Hidenori Suzuki
Journal:  Histol Histopathol       Date:  2020-02-06       Impact factor: 2.303

2.  A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm.

Authors:  George Bowman; Robert H Bonneau; Vernon M Chinchilli; Kevin J Tracey; Kevin M Cockroft
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

3.  Pharmaceutical Management for Subarachnoid Hemorrhage.

Authors:  Arnav Barpujari; Chhaya Patel; Rebecca Zelmonovich; Alec Clark; Devan Patel; Kevin Pierre; Kyle Scott; Brandon Lucke Wold
Journal:  Recent Trends Pharm Sci Res       Date:  2021

4.  Topical application of dexamethasone to prevent cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study.

Authors:  Luo Fei; Filimon Golwa
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 5.  Management of post-subarachnoid hemorrhage vasospasm.

Authors:  William Gump; Daniel T Laskowitz
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

6.  Expression change of interleukin-8 gene in rabbit basilar artery after subarachnoid hemorrhage.

Authors:  Yong Wang; Ming Zhong; Xian-Xi Tan; Yun-Jun Yang; Wei-Jian Chen; Wei Liu; Kuang Zheng
Journal:  Neurosci Bull       Date:  2007-05       Impact factor: 5.203

7.  Tocilizumab Reduces Vasospasms, Neuronal Cell Death, and Microclot Formation in a Rabbit Model of Subarachnoid Hemorrhage.

Authors:  Davide M Croci; Stefan Wanderer; Fabio Strange; Basil E Grüter; Sivani Sivanrupan; Lukas Andereggen; Daniela Casoni; Michael von Gunten; Hans Rudolf Widmer; Stefano Di Santo; Javier Fandino; Luigi Mariani; Serge Marbacher
Journal:  Transl Stroke Res       Date:  2021-01-06       Impact factor: 6.829

8.  Cerebral vasospasm pharmacological treatment: an update.

Authors:  Ioannis Siasios; Eftychia Z Kapsalaki; Kostas N Fountas
Journal:  Neurol Res Int       Date:  2013-01-31

Review 9.  Inflammation, cerebral vasospasm, and evolving theories of delayed cerebral ischemia.

Authors:  Kevin R Carr; Scott L Zuckerman; J Mocco
Journal:  Neurol Res Int       Date:  2013-08-22

10.  Influence of Fever and hospital-acquired infection on the incidence of delayed neurological deficit and poor outcome after aneurysmal subarachnoid hemorrhage.

Authors:  G Logan Douds; Bi Tadzong; Akash D Agarwal; Satish Krishnamurthy; Erik B Lehman; Kevin M Cockroft
Journal:  Neurol Res Int       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.